PathWhiz ID | Pathway | Meta Data |
---|---|---|
PW145407View Pathway |
drug action
Yohimbine Drug Metabolism Action PathwayHomo sapiens
|
Creator: Ray Kruger Created On: October 07, 2023 at 15:46 Last Updated: October 07, 2023 at 15:46 |
PW176298View Pathway |
Yohimbine Predicted Metabolism PathwayHomo sapiens
Metabolites of Yohimbine are predicted with biotransformer.
|
Creator: Omolola Created On: December 04, 2023 at 14:53 Last Updated: December 04, 2023 at 14:53 |
PW146580View Pathway |
drug action
Yttrium Y-90 Drug Metabolism Action PathwayHomo sapiens
|
Creator: Ray Kruger Created On: October 07, 2023 at 18:33 Last Updated: October 07, 2023 at 18:33 |
PW144666View Pathway |
drug action
Zafirlukast Drug Metabolism Action PathwayHomo sapiens
|
Creator: Ray Kruger Created On: October 07, 2023 at 14:10 Last Updated: October 07, 2023 at 14:10 |
PW176359View Pathway |
Zafirlukast Predicted Metabolism PathwayHomo sapiens
Metabolites of sildenafil are predicted with biotransformer.
|
Creator: Omolola Created On: December 07, 2023 at 15:32 Last Updated: December 07, 2023 at 15:32 |
PW000723View Pathway |
drug action
Zalcitabine Action PathwayHomo sapiens
Zalcitabine (ddc) is a dideoxynucleoside antiretroviral drug that when used in combination with zidovudine improves the viral load and CD4+ cell count of patients infected with Human Immunodeficiency Virus Type 1 (HIV-1). Zalcitabine is phosphorylated to it’s active form metabolite 2′,3′-dideoxycytidine 5′-triphosphate (ddCTP) in both healthy and infected cells. ddCTP competes with deoxycytidine triphosphate inhibiting the enzyme reverse transcriptase from using the substrates to elongate the viral DNA strand ultimately halting HIV replication.
|
Creator: WishartLab Created On: June 23, 2014 at 08:07 Last Updated: June 23, 2014 at 08:07 |
PW126448View Pathway |
drug action
Zalcitabine Action Pathway (New)Homo sapiens
Zalcitabine is a dideoxynucleoside used to treat HIV.
When HIV infects a cell, the virus first binds and fuses with the cell, releasing its nucleocapsid containing its RNA and reverse transcriptase into the cytosol of the cell. The reverse transcriptase converts the viral RNA into viral DNA in the cytosol. The viral DNA goes to the nucleus through the nuclear pore complex where it undergoes the process of transcription. The new viral RNA formed from transcription is transported back to the cytosol through the nuclear pore complex and translation occurs to produce viral proteins. These viral proteins are assembled and new HIV viruses bud from the cell.
Zalcitabine (dideoxycytidine) enters the cell and is converted into dideoxycytidine monophosphate by deoxycytidine kinase. UMP-CMP kinase then converts dideoxycytidine monophosphate into dideoxycytidine diphosphate. Dideoxycytidine diphosphate is metabolized to dideoxycytidine triphosphate via nucleoside diphosphate kinase.
Dideoxycytidine triphosphate is an analog of deoxycytidine-5'-triphosphate (dCTP). Dideoxycytidine triphosphate inhibits the activity of HIV-1 reverse transcriptase by competing with its substrate, dCTP and by incorporation into viral DNA. Dideoxycytidine triphosphate lacks the 3'-OH group which is needed to form the 5′ to 3′ phosphodiester linkage essential for DNA chain elongation, therefore, once dideoxycytidine triphosphate gets incorporated into DNA, this causes DNA chain termination, preventing the growth of viral DNA. Less viral proteins are therefore produced, and there is a reduction in new viruses being formed.
|
Creator: Karxena Harford Created On: December 05, 2021 at 22:08 Last Updated: December 05, 2021 at 22:08 |
PW145043View Pathway |
drug action
Zalcitabine Drug Metabolism Action PathwayHomo sapiens
|
Creator: Ray Kruger Created On: October 07, 2023 at 14:58 Last Updated: October 07, 2023 at 14:58 |
PW176308View Pathway |
Zalcitabine Predicted Metabolism PathwayHomo sapiens
Metabolites of Zalcitabine are predicted with biotransformer.
|
Creator: Omolola Created On: December 04, 2023 at 15:17 Last Updated: December 04, 2023 at 15:17 |
PW128435View Pathway |
drug action
Zaleplon Action PathwayHomo sapiens
Zaleplon, a nonbenzodiazepine hypnotic from the pyrazolopyrimidine class, serves as a sedative used for the short-term treatment of insomnia in adults. Functioning within the gamma-aminobutyric acid-benzodiazepine (GABABZ) receptor complex, it shares certain pharmacological attributes with benzodiazepines despite its distinct chemical structure. Classified as a schedule IV drug in the United States, Zaleplon interacts with the CNS GABAA-receptor chloride ionophore complex at benzodiazepine (BZ) omega-1 (BZ1, ο1) receptors. Its mechanism of action involves subunit modulation of the GABABZ receptor chloride channel macromolecular complex, and it also selectively binds to the brain omega-1 receptor found on the alpha subunit of the GABA-A/chloride ion channel receptor complex, enhancing t-butyl-bicyclophosphorothionate (TBPS) binding. Zaleplon, distinctly separate from benzodiazepines and other hypnotic agents, effectively addresses short-term insomnia by interacting with these receptor systems.
|
Creator: Dorsa Yahya Rayat Created On: August 28, 2023 at 19:40 Last Updated: August 28, 2023 at 19:40 |